Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Sang Hyub Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2174-9726; OpenAlex author ID A5046265004, A5100764633, A5109692776. Sources: OpenAlex.

Their work

Papers
51 (first author 7, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
118
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 3 papers · 2020: 2 papers · 2021: 5 papers · 2022: 7 papers · 2023: 4 papers · 2024: 9 papers · 2025: 3 papers · 2026: 4 papers

Papers 50 of 51

  1. Lorazepam and Survival in Asian Patients with Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.1007/s12029-026-01429-7↗
  2. Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial. Co-author DOI 10.1016/j.ejca.2026.116903↗
  3. Characteristics of Pancreatic Cancer-associated Ascites and Redefined Criteria for Bacterial Peritonitis. Co-author DOI 10.1097/mpa.0000000000002606↗
  4. Ferroptosis-based therapeutic strategy targeting iron metabolism and SLC7A11 overcomes oxaliplatin resistance in patient-derived pancreatic cancer organoids. Last author DOI 10.1186/s13046-026-03745-z↗
  5. ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167625↗
  6. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Co-author DOI 10.1093/clinchem/hvaf066↗
  7. Comprehensive molecular analysis of 26 newly established human pancreatic ductal adenocarcinoma cell lines reveals two clusters with variating drug sensitiviti… Co-author DOI 10.1186/s12935-025-03671-8↗
  8. Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancer. Last author DOI 10.1002/jcsm.13437↗
  9. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.12049↗
  10. Establishment, characterization, and biobanking of 36 pancreatic cancer organoids: prediction of metastasis in resectable pancreatic cancer. Co-author DOI 10.1007/s13402-024-00939-5↗
  11. Safety and Efficacy of Neoadjuvant SABR in Pancreatic Cancer: Effect of Magnetic Resonance Imaging-Guided Respiratory-Gated Adaptive Radiation Therapy. Co-author DOI 10.1016/j.adro.2023.101312↗
  12. Whole-genome bisulfite sequencing identifies stage- and subtype-specific DNA methylation signatures in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.109414↗
  13. Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX. Last author DOI 10.1177/17588359241290482↗
  14. Enhanced Anti-tumor Effect of Flavopiridol in Combination With Gemcitabine in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16905↗
  15. Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib. Co-author DOI 10.3390/cancers16051056↗
  16. Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. Co-author DOI 10.4062/biomolther.2023.109↗
  17. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Co-author DOI 10.1002/jhbp.1050↗
  18. Combination of chemotherapy and focused ultrasound for the treatment of unresectable pancreatic cancer: a proof-of-concept study. Co-author DOI 10.1007/s00330-022-09271-8↗
  19. Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET/MRI and CA 19-9. Last author DOI 10.1186/s40644-023-00565-8↗
  20. Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells. First author DOI 10.3390/cancers15092642↗
  21. Accelerated Pancreatobiliary MRI for Pancreatic Cancer Surveillance in Patients With Pancreatic Cystic Neoplasms. Co-author DOI 10.1002/jmri.28189↗
  22. Cytokine-Induced Killer Cell Immunotherapy Combined With Gemcitabine Reduces Systemic Metastasis in Pancreatic Cancer: An Analysis Using Preclinical Adjuvant T… Last author DOI 10.1097/mpa.0000000000002176↗
  23. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic a… Co-author DOI 10.1177/17588359221119539↗
  24. Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX. Co-author DOI 10.3389/fonc.2022.945829↗
  25. Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate on Computed … Co-author DOI 10.5009/gnl210123↗
  26. Corrigendum: Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate… Co-author DOI 10.5009/gnl210123.e↗
  27. Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies. Co-author DOI 10.5009/gnl210166↗
  28. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, p… Co-author DOI 10.1177/17588359211056179↗
  29. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching … First author DOI 10.1186/s12885-021-08277-7↗
  30. Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Ca… Co-author DOI 10.3390/cancers13061196↗
  31. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. First author DOI 10.5009/gnl19182↗
  32. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
  33. Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer. First author DOI 10.1016/j.hbpd.2020.05.005↗
  34. Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach. Co-author DOI 10.5306/wjco.v11.i9.747↗
  35. The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort. First author DOI 10.1002/cam4.2617↗
  36. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Co-author DOI 10.1002/jhbp.648↗
  37. Comparison of Adjuvant Chemotherapy and Chemoradiation Therapy Efficacy for Pancreatic Cancer After R0 Resection: A Propensity Score-Matched Analysis Co-author DOI 10.21203/rs.2.12295/v1↗
  38. Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells. Co-author DOI 10.21873/anticanres.12624↗
  39. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i12.505↗
  40. Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.5009/gnl18220↗
  41. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreati… Co-author DOI 10.1097/md.0000000000005702↗
  42. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. Co-author DOI 10.5009/gnl16307↗
  43. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer. Co-author DOI 10.1111/jgh.13075↗
  44. Lower maximum standardized uptake value of fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography imaging in pancreatic d… Co-author DOI 10.1016/j.amjsurg.2014.06.038↗
  45. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. First author DOI 10.3346/jkms.2015.30.7.917↗
  46. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who hav… First author DOI 10.1159/000356158↗
  47. Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Co-author PMID 23564788↗
  48. The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318221c903↗
  49. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318249d62e↗
  50. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients. Co-author DOI 10.1111/j.1440-1827.2011.02772.x↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ji Kon Ryu · 34 shared papers, 2011–2026 · strength 4.81
  2. Woo Hyun Paik · 28 shared papers, 2013–2026 · strength 4.71
  3. In Rae Cho · 15 shared papers, 2021–2026 · strength 3.21
  4. Yong‐Tae Kim · 25 shared papers, 2012–2025 · strength 3.16
  5. Jin Ho Choi · 14 shared papers, 2018–2026 · strength 2.44
  6. Jin‐Young Jang · 11 shared papers, 2019–2025 · strength 1.93
  7. Wooil Kwon · 9 shared papers, 2019–2026 · strength 1.61
  8. Ja‐Lok Ku · 7 shared papers, 2022–2026 · strength 1.44
  9. Do‐Youn Oh · 7 shared papers, 2019–2025 · strength 1.22
  10. Jung Won Chun · 7 shared papers, 2019–2025 · strength 1.06
  11. Soon‐Chan Kim · 4 shared papers, 2022–2025 · strength 0.82
  12. Hongbeom Kim · 5 shared papers, 2019–2024 · strength 0.72
  13. Eui Kyu Chie · 4 shared papers, 2021–2024 · strength 0.70
  14. Sang Myung Woo · 5 shared papers, 2011–2025 · strength 0.62
  15. Gunn Huh · 5 shared papers, 2018–2021 · strength 0.58
  16. Min Woo Lee · 3 shared papers, 2023–2024 · strength 0.58
  17. Jeong Hee Yoon · 3 shared papers, 2022–2024 · strength 0.58
  18. Jeong Min Lee · 3 shared papers, 2022–2024 · strength 0.58
  19. Woo Jin Lee · 3 shared papers, 2022–2025 · strength 0.56
  20. Min Su You · 5 shared papers, 2018–2021 · strength 0.55
  21. Jae Young Lee · 2 shared papers, 2023–2026 · strength 0.51
  22. J.H. Lee · 3 shared papers, 2022–2024 · strength 0.48
  23. Sang Kook Lee · 3 shared papers, 2022–2024 · strength 0.48
  24. Ju Eun Maeng · 2 shared papers, 2024–2025 · strength 0.47
  25. Kwang Hyun Chung · 4 shared papers, 2015–2024 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.